337 related articles for article (PubMed ID: 8499348)
1. Metabolism of the oral contraceptive steroids ethynylestradiol, norgestimate and 3-ketodesogestrel by a human endometrial cancer cell line (HEC-1A) and endometrial tissue in vitro.
Wild MJ; Rudland PS; Back DJ
J Steroid Biochem Mol Biol; 1993 May; 45(5):407-20. PubMed ID: 8499348
[TBL] [Abstract][Full Text] [Related]
2. Metabolism of the oral contraceptive steroids ethynylestradiol and norgestimate by normal (Huma 7) and malignant (MCF-7 and ZR-75-1) human breast cells in culture.
Wild MJ; Rudland PS; Back DJ
J Steroid Biochem Mol Biol; 1991 Oct; 39(4A):535-43. PubMed ID: 1911442
[TBL] [Abstract][Full Text] [Related]
3. Gastrointestinal metabolism of contraceptive steroids.
Back DJ; Madden S; Orme ML
Am J Obstet Gynecol; 1990 Dec; 163(6 Pt 2):2138-45. PubMed ID: 2147818
[TBL] [Abstract][Full Text] [Related]
4. Norgestimate: a clinical overview of a new progestin.
Bringer J
Am J Obstet Gynecol; 1992 Jun; 166(6 Pt 2):1969-77. PubMed ID: 1605287
[TBL] [Abstract][Full Text] [Related]
5. A norgestimate-containing oral contraceptive: review of clinical studies.
Kafrissen ME
Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1196-202. PubMed ID: 1415446
[TBL] [Abstract][Full Text] [Related]
6. Desogestrel, norgestimate, and gestodene: the newer progestins.
Kaplan B
Ann Pharmacother; 1995; 29(7-8):736-42. PubMed ID: 8520092
[TBL] [Abstract][Full Text] [Related]
7. The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel.
Gentile DM; Verhoeven CH; Shimada T; Back DJ
J Pharmacol Exp Ther; 1998 Dec; 287(3):975-82. PubMed ID: 9864282
[TBL] [Abstract][Full Text] [Related]
8. Effect of the progestogens, gestodene, 3-keto desogestrel, levonorgestrel, norethisterone and norgestimate on the oxidation of ethinyloestradiol and other substrates by human liver microsomes.
Back DJ; Houlgrave R; Tjia JF; Ward S; Orme ML
J Steroid Biochem Mol Biol; 1991 Feb; 38(2):219-25. PubMed ID: 2004043
[TBL] [Abstract][Full Text] [Related]
9. Studies on the role of intestinal bacteria in metabolism of synthetic and natural steroid hormones.
Adlercreutz H; Pulkkinen MO; Hämäläinen EK; Korpela JT
J Steroid Biochem; 1984 Jan; 20(1):217-29. PubMed ID: 6231418
[TBL] [Abstract][Full Text] [Related]
10. A comparative randomized trial on the impact of two low-dose oral contraceptives on ovarian activity, cervical permeability, and endometrial receptivity.
Rossmanith WG; Steffens D; Schramm G
Contraception; 1997 Jul; 56(1):23-30. PubMed ID: 9306028
[TBL] [Abstract][Full Text] [Related]
11. Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters.
Wiegratz I; Jung-Hoffmann C; Gross W; Kuhl H
Contraception; 1998 Aug; 58(2):83-91. PubMed ID: 9773262
[TBL] [Abstract][Full Text] [Related]
12. Protein binding of the contraceptive steroids gestodene, 3-keto-desogestrel and ethinylestradiol in human serum.
Kuhnz W; Pfeffer M; al-Yacoub G
J Steroid Biochem; 1990 Feb; 35(2):313-8. PubMed ID: 2308344
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of a monophasic and a triphasic oral contraceptive containing norgestimate.
Corson SL
Am J Obstet Gynecol; 1994 May; 170(5 Pt 2):1556-61. PubMed ID: 8178906
[TBL] [Abstract][Full Text] [Related]
14. 17 beta-Hydroxysteroid dehydrogenase activity in endometrial cancer cells: different metabolic pathways of estradiol in hormone-responsive and non-responsive intact cells.
Castagnetta LA; Montesanti AM; Granata OM; Oliveri G; Sorci CM; Amodio R; Liquori M; Carruba G
J Steroid Biochem Mol Biol; 1995 Dec; 55(5-6):573-9. PubMed ID: 8547184
[TBL] [Abstract][Full Text] [Related]
15. Influence of gestodene and desogestrel as components of low-dose oral contraceptives on the pharmacokinetics of ethinyl estradiol (EE2), on serum CBG and on urinary cortisol and 6 beta-hydroxycortisol.
Hammerstein J; Daume E; Simon A; Winkler UH; Schindler AE; Back DJ; Ward S; Neiss A
Contraception; 1993 Mar; 47(3):263-81. PubMed ID: 8462317
[TBL] [Abstract][Full Text] [Related]
16. Oral contraceptives containing 20 or 30 micrograms ethinylestradiol and 150 micrograms desogestrel: pharmacokinetics and pharmacodynamic parameters.
Jung-Hoffmann C; Fitzner M; Kuhl H
Horm Res; 1991; 36(5-6):238-46. PubMed ID: 1823082
[TBL] [Abstract][Full Text] [Related]
17. Mode of action of dl-norgestrel and ethinylestradiol combination in postcoital contraception. II. Effect of postovulatory administration on ovarian function and endometrium.
Ling WY; Wrixon W; Zayid I; Acorn T; Popat R; Wilson E
Fertil Steril; 1983 Mar; 39(3):292-7. PubMed ID: 6402387
[TBL] [Abstract][Full Text] [Related]
18. Metabolism of the contraceptive steroid desogestrel by the intestinal mucosa.
Madden S; Back DJ; Martin CA; Orme ML
Br J Clin Pharmacol; 1989 Mar; 27(3):295-9. PubMed ID: 2524206
[TBL] [Abstract][Full Text] [Related]
19. The endometrial cancer cell lines Ishikawa and HEC-1A, and the control cell line HIEEC, differ in expression of estrogen biosynthetic and metabolic genes, and in androstenedione and estrone-sulfate metabolism.
Hevir-Kene N; Rižner TL
Chem Biol Interact; 2015 Jun; 234():309-19. PubMed ID: 25437045
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris.
Lucky AW; Henderson TA; Olson WH; Robisch DM; Lebwohl M; Swinyer LJ
J Am Acad Dermatol; 1997 Nov; 37(5 Pt 1):746-54. PubMed ID: 9366821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
